由PSMA4过度表达引起的代谢重编程有助于在多发性骨髓瘤中促进博特佐米布耐药性
Han Yu1, Chengli Wu1, Jie He2
1Department of Oncology, Navy No.905 Hospital of PLA, Naval Medical University, Shanghai, 200052, China.
Annals of hematology
|January 4, 2025
概括
多发性髓瘤仍然是无法治愈的. 过度表达PSMA4基因通过增加氧化酸化和激活HIF-1α信号来驱动化学抵抗,从而提供了一个潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢过程中的代谢.
背景情况:
- 多发性骨髓瘤 (MM) 是一种无法治愈的血液性恶性瘤,其特点是复发率高和化学抵抗性.
- 了解药物耐药性背后的分子机制对于开发有效的治疗策略至关重要.
研究的目的:
- 确定关键的基因和途径参与多发性骨髓瘤的化学抵抗.
- 调查发现的枢纽基因PSMA4在代谢重编程和药物耐药性中的作用.
主要方法:
- 在新诊断的骨髓瘤和二次性血细胞白血病之间,对差异性表达基因 (DEGs) 的权重基因共同表达网络分析 (WGCNA).
- 使用海马XF.建立耐药性髓瘤细胞系和代谢分析.
- 在体外实验包括基因淘汰和途径分析.
主要成果:
- 据WGCNA的统计,PSMA4是关键的枢纽基因,与外骨髓性侵袭和化学抵抗有关.
- 博尔特佐米布耐药性髓瘤细胞显示PSMA4表达升高,氧化酸化增加和ROS水平更高.
- 通过抑制氧化酸化和激活HIF-1α信号通路,PSMA4敲击使抵抗细胞重新敏感,促进抗亡活性.
结论:
- 通过增强的氧化酸化,PSMA4在推动新陈代谢重编程方面发挥着关键作用,导致缺氧状态并激活多发性骨髓瘤中HIF-1α信号.
- 这一途径通过促进抗亡效应,显著促进了博尔特佐米布耐药性,突出显示了PSMA4作为潜在的治疗标.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
10:26In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
12.1K
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
